214 reports of this reaction
1.3% of all ENCORAFENIB reports
#18 most reported adverse reaction
VISION BLURRED is the #18 most commonly reported adverse reaction for ENCORAFENIB, manufactured by Array BioPharma Inc.. There are 214 FDA adverse event reports linking ENCORAFENIB to VISION BLURRED. This represents approximately 1.3% of all 16,241 adverse event reports for this drug.
Patients taking ENCORAFENIB who experience vision blurred should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISION BLURRED is a less commonly reported adverse event for ENCORAFENIB, but still significant enough to appear in the safety profile.
In addition to vision blurred, the following adverse reactions have been reported for ENCORAFENIB:
The following drugs have also been linked to vision blurred in FDA adverse event reports:
VISION BLURRED has been reported as an adverse event in 214 FDA reports for ENCORAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISION BLURRED accounts for approximately 1.3% of all adverse event reports for ENCORAFENIB, making it a notable side effect.
If you experience vision blurred while taking ENCORAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.